Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bright Minds Biosciences Inc | DRUG | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.21 | 06:00:14 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.21 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.93 - 6.44 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.21 | USD |
Bright Minds Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.4M | 4.46M | - | 0 | -7.37M | -1.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Bright Minds Biosciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DRUG Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.13 | 1.28 | 1.10 | 1.24 | 20,582 | 0.08 | 7.08% |
| 1 Month | 1.02 | 1.28 | 1.0101 | 1.15 | 12,654 | 0.19 | 18.63% |
| 3 Months | 1.50 | 1.67 | 0.93 | 1.20 | 18,510 | -0.29 | -19.33% |
| 6 Months | 1.40 | 2.39 | 0.93 | 1.59 | 27,370 | -0.19 | -13.57% |
| 1 Year | 3.05 | 6.44 | 0.93 | 3.67 | 191,249 | -1.84 | -60.33% |
| 3 Years | 44.75 | 44.75 | 0.93 | 10.36 | 1,439,326 | -43.54 | -97.30% |
| 5 Years | 44.75 | 44.75 | 0.93 | 10.36 | 1,439,326 | -43.54 | -97.30% |
Bright Minds Biosciences Description
| Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. |
